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Background: A single intake of monosodium glutamate (MSG) may cause headache and increased muscle
sensitivity. We conducted a double-blinded, placebo-controlled, crossover study to examine the effect of repeated
MSG intake on spontaneous pain, mechanical sensitivity of masticatory muscles, side effects, and blood pressure.
Methods: Fourteen healthy subjects participated in 5 daily sessions for one week of MSG intake (150 mg/kg) or
placebo (24 mg/kg NaCl) (randomized, double-blinded). Spontaneous pain, pressure pain thresholds and tolerance
levels for the masseter and temporalis muscles, side effects, and blood pressure were evaluated before and 15, 30,
and 50 min after MSG intake. Whole saliva samples were taken before and 30 min after MSG intake to assess
glutamate concentrations.
Results: Headache occurred in 8/14 subjects during MSG and 2/14 during placebo (P = 0.041). Salivary glutamate
concentrations on Day 5 were elevated significantly (P < 0.05). Pressure pain thresholds in masseter muscle were
reduced by MSG on Day 2 and 5 (P < 0.05). Blood pressure was significantly elevated after MSG (P < 0.040).
Conclusion: In conclusion, MSG induced mechanical sensitization in masseter muscle and adverse effects such as
headache and short-lasting blood pressure elevation for which tolerance did not develop over 5 days of MSG
intake.
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Temporomandibular Disorders (TMD) affect approxi-
mately 10% of the population [1,2]. The principal symp-
tom of TMD that most often leads patients to seek
medical treatment is pain in the temporomandibular joint
and/or masticatory muscles [1]. Around 70% of TMD
patients report masticatory muscle pain and are described
as suffering from myofascial TMD [3]. In the majority of
myofascial TMD cases, there is little evidence of ongoing
pathological change in masticatory muscles, and, conse-
quently, a number of alternative mechanisms have been
proposed to explain pathogenesis of this pain [1,3]. Of* Correspondence: akiko.shimada@odontologi.au.dk
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in any medium, provided the original work is pthese potential mechanisms, life-style related factors may
play an important role in development and maintenance
of muscle pain in myofascial TMD. For example, chronic
stress has been speculated to lead to parafunctional activ-
ities such as repetitive tooth clenching or grinding that
then produces strain injury to masticatory muscles leading
to pain [4-6], although the relationship between bruxism
and craniofacial pain may be more complex [7,8]. Diet
may be another important life-style related factor contrib-
uting the muscle pain in myofascial TMD, as it has been
reported that TMD patients alter their diet to avoid ex-
acerbating pain associated with mastication of certain
foods [9]. However, very little is currently known about
the interaction between food intake and pain in TMD.
Consumption of certain foods is thought to precipitate
or aggravate other chronic craniofacial pain conditions.
One postulated food trigger for migraine headaches iss an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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enhancer in many snack and fast foods [10]. Indeed,
total dietary consumption of glutamate ranges from 50–
200 mg/kg/day [11,12]. Of note, healthy young men who
consumed a single dose of 150 mg/kg MSG had a sig-
nificant increase in headache and craniofacial muscle
sensitivity as well as an elevated systolic blood pressure
[13], suggesting that MSG consumption may trigger
more types of craniofacial pain than just headaches. A
significant amount of systemically administered glutam-
ate is known to be taken up by skeletal muscles, includ-
ing the masticatory muscles [14]. The resulting elevation
of interstitial glutamate concentration sensitizes muscle
nociceptors to mechanical stimuli [15]; an effect which
could underlie reports of craniofacial muscle pain sensi-
tivity in healthy young men given MSG [13]. Further,
there is evidence that glutamate concentrations are ele-
vated in painful regions of masticatory muscles of myo-
fascial TMD patients compared to healthy controls [16].
Although a single 150 mg/kg dose of MSG did result
in a demonstrable increase in craniofacial sensitivity in
young healthy men, more regular consumption of this
quantity of MSG may result in tolerance to the acute
sensitizing effects of MSG [13]. On the other hand,
chronic daily administration of 150 mg/kg of MSG
might lead to the accumulation of MSG in masticatory
muscles, which might be manifested by enhanced cra-
niofacial sensitivity reminiscent of symptoms reported
by myofascial TMD patients. The current study was
therefore conducted to assess the impact of 5 days of
consumption of 150 mg/kg MSG on craniofacial pain
sensitivity in healthy subjects.
Methods
Study design and subjects
This study was performed as a double-blinded, placebo-
controlled cross-over trial. The study protocol was
approved by the local ethics committee (approval No.
20060040 – amendment No. 2 of March 2010) and
informed consent was obtained from all subjects. The
study was conducted in accordance with the Declaration
of Helsinki. Randomization was performed by a com-
puter and the examiners were blinded until after finish-
ing data collection on all subjects.
Fourteen healthy adult (> 18 years) subjects (9 women
and 5 men, mean age 27.6 ± 1.7 years, mean bodyweight
64.1 ± 2.5 kg) were included in the study through the
webpage (www.forsoegsperson.dk) and among staffs and
students at the Department of Dentistry, Aarhus Univer-
sity. Exclusion criteria were: orofacial pain, chronic ill-
ness, e.g. uncontrolled hypertension, allergy to MSG,
asthma, diabetes mellitus, body mass index > 25 [13].
Each subject participated in 10 (2 × 5) sessions (Monday
through Friday in two consecutive weeks). In one week,the subjects received MSG, and in the other week, placebo
(see below), in randomized order.Baseline measurements
On the first day, the bodyweight of the subject was mea-
sured with the use of a digital scale. The subjects were
asked to fast for at least 3 hours before each session. In
each of the 10 sessions at baseline (BL), after a 10 min rest,
a resting whole saliva sample was collected using the drain-
ing method [17]. The collection of saliva samples took
place in a quiet room. The subjects were seated upright in
a chair with the head slightly bent forward, and instructed
to drool into a plastic cup for 10 min [18]. The subjects
were then asked to rate spontaneous pain (if any) on a 0-
10 numerical rating scale (NRS, 0 = no pain, 10 = most im-
aginable pain). Then, pressure pain thresholds (PPT) and
pressure pain tolerance levels (PPTol) of the left masseter
and temporalis muscles were measured [19]. Systolic and
diastolic blood pressure (BP) and heart rate (HR) were also
measured with the use of a digital blood pressure monitor
(UA-767plus; A&D Medical, Abingdon, UK).Administration of monosodium glutamate (MSG) or
placebo
In each session of the MSG week, a drink was prepared
of 400 ml sugar-free lemon soda (Spirit lightW, Coop) by
a research assistant in a separate room. The beverage
contained carbon dioxide, citric acid, sodium citrate,
aromas, artificial sweeteners (aspartame, acesulfame po-
tassium) and sodium benzoate. MSG (150 mg MSG per
kg bodyweight) was added to the soda. In the placebo
week, 24 mg per kg bodyweight of NaCl was added to
the drink instead of MSG to create a similar taste. The
drink was ingested over a few min [13].Pressure pain thresholds and pressure pain tolerance
thresholds
An algometer (Somedic, Hörby, Sweden) was use to as-
sess PPT and PPTol in the masseter and temporalis
muscles. To undertake these measurements, the subject’s
head was gently supported by the opposite hand of the
examiner and the subject was instructed to keep his/her
teeth slightly apart during the measurements [3,19]. Sub-
jects were instructed to press a button when the force
applied by the examiner just became painful (PPT) or
when they could no longer tolerate the force being ap-
plied (PPTol). PPT (triplicates) and PPTol (single mea-
sures) for left masseter and left temporalis were repeated
in all sessions 15, 30, and 50 min after drinking the bev-
erage. Only the left side was assessed, since it has been
shown that there are no overall differences between
sides regarding pressure sensitivity [13].
Figure 1 The mean (± SEM) numerical rating scale (NRS)
spontaneous pain reports from the subjects over 5 days of
monosodium glutamate (MSG) and placebo intervention
(N = 14). Neither intervention resulted in significant spontaneous
pain reports.
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The subjects were asked to rate any pain on a 0-10 NRS at
time-points 15, 30 and 50 min after the drink. In addition,
they were asked about the following adverse effects: Head-
ache, nausea, dizziness, feeling of chest pressure, burning
sensation of skin, tiredness, sore jaw, stomach ache, and
“other, please specify” [11,13]. They answered “yes” or
“no” to each adverse reaction.
Measurement of glutamate levels in resting whole saliva
Two resting saliva samples were collected in each session;
one prior to and another 30 min after drinking the bever-
age. The whole saliva samples were pipetted into test tubes
and placed on ice immediately after collection and then
kept in a freezer (-80°C) until analysis. Each sample was
centrifuged before measurements of glutamate (1500 g for
5 min). The concentration of glutamate in the whole saliva
samples was determined with a commercially available kit
(L-Glutaminsäure/L-Glutamate, Thermo Fisher Scientific
Inc., Australia) using the photometric analyzer Konelab 30i
(Thermo Clinical Labsystems/ILS Laboratories Scandinavia,
Denmark). The molecular weight of glutamate is 146 g/mol.
The standard (calibrator) in the kit was 0.1 g/L correspon-
ding to 684.9 μM. Upper test limits for the kit was
3592.00 μM. A sample volume of 10 μL of saliva per mea-
surement was used. Duplicate measurements were per-
formed for each sample at a wavelength of 492 nm. Values of
salivary glutamate were given in μM.
Blood pressure and heart rate
BP and HR measurements with a digital blood pressure
monitor (UA-767puls; A&D Medical, Abingdon, UK)
were repeated in all sessions at 15, 30, and 50 min after
drinking the beverage.
Statistics
All data are presented as means ± standard error of the
mean (SEM). Levels of P less than 0.05 were considered
statistically significant. Spontaneous pain, PPT, PPTol,
BP, HR, and glutamate concentration were analyzed with
3-way repeated measurement (RM) analyses of variance
(ANOVAs) with intervention (MSG vs. placebo), day
(Day 1-5 in each week) and time (BL, 15, 30, 50 min) as
factors. For glutamate concentration only two time peri-
ods (BL and 30 min) were used. When appropriate, post
hoc Tukey Honestly Significant Difference (HSD) tests
with corrections for multiple comparisons were per-
formed. Occurrence of side effects was compared be-
tween weeks with McNemar´s test.
Results
Spontaneous pain
Three subjects experienced spontaneous pain in the cra-
niofacial region in the MSG week (maximum pain level 6,3 and 2, respectively) and one subject experienced pain
(only on Day 1, maximum pain level 3) in the placebo
week. However, group mean pain scores were low and not
significantly influenced by intervention (MSG vs. Placebo),
day (Day 1-5), or time (BL, 15, 30, 50 min after intake)
(P > 0.174) (Figure 1).
Pressure pain thresholds (PPT) and pressure pain
tolerance (PPTol)
PPT and PPTol measures were normalized to the BL value
on Day 1 before analyses. There was no main effect of
intervention (MSG vs. placebo) on PPT in left masseter
(P = 0.159, F = 2.281). There was a main effect of day (P =
0.002, F = 4.996) and time (P = 0.007, F = 4.867) and a
tendency towards a significant interaction between inter-
vention and day (P = 0.079, F = 2.249). Post hoc tests
revealed that left masseter PPT was significantly reduced
on Day 2 and 3 compared to Day 1 (P < 0.048; Figure 2).
Within sessions, left masseter PPT was increased at the 30
and 50 min time-points compared to BL (P < 0.032; Data
not shown). Post hoc analysis of the interaction between
intervention and day showed a significant reduction
in normalized left masseter PPT on Day 2 and 5 in the
MSG week compared to placebo and Day 1 (P < 0.029)
(Figure 2). Left temporalis PPT was not influenced by
intervention (P = 0.411, F = 0.729) or day (P = 0.337, F =
1.169) but there was a main effect of time (P = 0.002, F =
6.388) (Figure 2). Post hoc tests revealed that left tempor-
alis PPT was increased at 15, 30 and 50 min compared
with BL within sessions (P < 0.023; Data not shown).
There was no main effect of intervention (P = 0.645, F =
0.225) or time (P = 0.254, F = 1.420) on left masseter
PPTol, but there was a main effect of day (P = 0.026, F =
3.054). The post hoc test showed a significant decrease in
Figure 2 The overall (± SEM) mean relative Pressure Pain Threshold (PPT) or Pressure Pain Tolerance (PPTol) for each day (N = 14).
There was a trend in PPT values in both muscles and PPTol values in the temporalis muscle to increase due to repeated measurement during
each daily session, which resulted in mean overall values that exceeded 100% on all 5 days during placebo intervention. The masseter muscle
PPT and PPTol measured on Day 2 and 3 were both significantly decreased compared to Day 1 (#: P < 0.05), but this difference occurred
independent of intervention. The masseter muscle PPT was, however, significantly lower after monosodium glutamate (MSG) ingestion than after
placebo ingestion on Day 2 and 5 (*: P < 0.05). There was no effect of intervention or day on the PPT and PPTol measured from the
temporalis muscle.
Table 1 The percentage of subjects reporting side effects
at least once over the 5 days of intervention
Side effect MSG Placebo McNemar’s test
Nausea 57.1 21.4 P = 0.182
Headache* 57.1 7.1 P = 0.041
Dizziness 35.7 0.0 P = 0.074
Chest Pressure 28.6 0.0 P = 0.134
Burning 21.4 7.1 P = 0.617
Fatigue 50.0 28.6 P = 0.074
Sore Jaw 57.1 35.7 P = 0.450
Stomachache 35.7 7.1 P = 0.134
Other* 57.1 14.3 P = 0.023
Other included reports of numbness in appendages, feeling cold,
and heartburn.
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(P < 0.047) (Figure 2). Left temporalis PPTol was not sig-
nificantly influenced by intervention (P = 0.943, F = 0.005)
or day (P = 0.700, F = 0.550) but there was a main effect
of time (P = 0.038, F = 3.156) (Figure 2). Left temporalis
PPTol was significantly increased at 50 min compared
with BL (P = 0.044; Data not shown).
Adverse effects
A greater number of subjects reported adverse effects in
the MSG week than in the placebo week (Table 1). The
number of subjects who reported headache was signifi-
cantly higher during the MSG week than during the pla-
cebo week. The daily incidence of the various side effects
is shown in Figure 3. As can been seen in Figure 3, most
side effects were more frequent at the beginning of inter-
vention and tended to be less commonly reported in the
final 2 days of MSG intervention. In contrast, some side
effects, notably headache and stomach ache, had a similar
frequency of occurrence throughout the entire 5 days
MSG intervention.
Glutamate levels in whole saliva
Average trough (daily baseline) levels of salivary glutamate
were 17 ± 3 μM in during the 5 days of MSG and24 ± 4 μM during the 5 days of placebo. Average peak
levels of salivary glutamate were 220 ± 61 μM in MSG
week and 14 ± 2 μM in placebo week. The ANOVA of
glutamate concentration demonstrated a significant inter-
action between intervention and day (P = 0.028, F =
3.010). Post hoc analyses showed that glutamate levels
were significantly higher on Day 2 through Day 5 in the
MSG week compared with the placebo week (P < 0.05).
Figure 3 The vertical bar chart shows the frequency of side effects reports by > 30% of the subjects over 5 days of monosodium
glutamate (MSG) (black) and 5 days of placebo (white) intervention. For most side effects, such as nausea and fatigue, there was a peak in
reports on the second or third day of administration followed by a gradual decline in reports. There were substantially fewer reports of side
effects in the placebo group, with the exception of reports of jaw soreness, which peaked during the first session and then declined. The
Occurrence of headache and other side effects showed a significant difference between the interventions by McNemar’s test (*: P < 0.05).
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nificantly higher than that on Day 1 (P < 0.05) (Figure 4).Figure 4 The mean (± SEM) glutamate concentration in saliva
during the monosodium glutamate (MSG) and placebo
intervention (N = 14). There was a significant increase in the
concentration of glutamate in the saliva on Day 5, compared to Day
1 (#: P < 0.05). Note that there was a tendency for the glutamate
concentration to increase each day of the 5 days MSG session,
which suggests that a modest accumulation of glutamate was
occurring. On Day 2 through Day 5, the concentration of glutamate
was significantly higher in the MSG session compared to placebo
session (*: P < 0.05).Blood pressure (systolic: sBP: diastolic: dBP) and heart
rate (HR)
There were no main effects of intervention (P = 0.079,
F =3.727) or day (P = 0.324, F = 1.200) on sBP. However,
there was a main effect of time (P = 0.026, F = 3.518)
and a significant interaction between intervention and
time (P = 0.007, F = 4.811). The post hoc test of the
main time effect showed that sBP was elevated 15 min
after intake (P = 0.022). A post hoc test of the interven-
tion × time interaction revealed that in the MSG ses-
sions (P < 0.040) but not in placebo sessions (P > 0.900),
sBP was elevated 15 and 30 min after intake (Figure 5).
There were no main effects on dBP of intervention
(P = 0.067, F = 4.132), day (P = 0.602, F = 0.692), or time
(P = 0.099, F = 2.270). However, there was a significant
interaction between intervention and time (P = 0.005,
F = 5.049). The post hoc test indicated that dBP was sig-
nificantly elevated in the MSG sessions at 15 and
30 min after intake compared with placebo sessions (P <
0.043) (Figure 5).
There were no main effects of intervention (P = 0.412,
F = 0.728) or day (P = 0.265, F = 1.356) on HR, but there
was a significant effect of time (P < 0.001, F = 10.104).
HR decreased over time and was significantly lower than
BL at 15, 30 and 50 min after intake of either substance
(P < 0.003).Result of blinding procedure
At the end of each 5 days session, subjects were asked to indi-
cate which substance they thought they had received. Sub-
jects correctly identified the substance given to them 88% of
the time, suggesting that due to the increased number of side
effects experienced by many subjects who received MSG,
most subjects were able to guess what they were receiving.
Figure 5 The time course of changes in mean (± SEM) systolic
and diastolic blood pressure during monosodium glutamate
(MSG) and placebo intervention. As there was no effect of day, a
grand average of the results of all 5 days is shown. Note that there
was a small, but significant (*: P < 0.05) increase in both systolic and
diastolic blood pressure 15 and 30 minutes after ingestion of MSG,
but no change in blood pressure after placebo.
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The present study was conducted to probe whether,
compared to a single administration, repeated intake of
MSG could lead to increased complaints of untoward
affects and evidence of accumulation of glutamate. MSG
(150 mg/kg) was administered daily for 5 days and pain
sensitivity and side effects monitored. Daily intake of this
amount of MSG did not result in significant reports of
spontaneous pain. However, it did lead to a sustained
mechanical sensitization of the masseter muscle that
lasted for the duration of MSG administration. This pain
sensitizing effect of MSG was not observed in the tem-
poralis muscle, suggesting that the effect was site spe-
cific. Daily intake of MSG also caused headaches and
dizziness for at least one day out of five in 57% of sub-
jects. Although tolerance to most side effects of MSG
administration appeared to occur, as evidenced by a de-
crease in the frequency of side effect complaints, the fre-
quency of headache reports remained relatively constant
over the 5 days of MSG ingestion. This suggests that tol-
erance to the headache inducing effects of MSG may not
occur. There was also no apparent tolerance to the abil-
ity of MSG administration to increased systolic and dia-
stolic blood pressure over the 5 days intervention.
Baseline salivary concentrations of glutamate remainedconstant and were not different between the MSG and
placebo sessions. These concentrations are similar to a
previous study that reported mean saliva concentrations
of glutamate of 18±1 μM in 18 subjects [20]. However, ad-
ministration of MSG tended to increase salivary glutamate
concentration each day, which suggests the potential that
accumulation might have been occurring. These findings
suggest that daily consumption of elevated amounts of
MSG increases craniofacial pain symptoms in otherwise
healthy subjects.
There are some differences in the response properties
of the masseter and temporalis muscles to glutamate
that may underlie the finding of a masseter muscle se-
lective mechanical sensitizing effect of MSG. Elevated
concentrations of glutamate induce mechanical sensi-
tization of masticatory muscle nociceptors through acti-
vation of peripheral NMDA receptors [15,21]. It has
been found that there is a lower expression of NMDA
receptors by nociceptors that innervate the temporalis
muscle and that the response of temporalis nociceptors
to peripheral NMDA receptor activation is less robust
than masseter muscle nociceptors [22,23]. Thus, it is
possible that there is also a lower expression of periph-
eral NMDA receptors by nociceptors that innervate
the temporalis muscle in healthy human subjects, which
results in the temporalis muscle being less sensitive to
orally consumed MSG than the masseter muscle [24].
There was a very consistent, albeit relatively small, in-
crease in both systolic and diastolic blood pressure after
oral intake of MSG each day. There is recent evidence
that increased dietary intake of glutamate over a 5 year
period is correlated with an increase in systolic blood
pressure, which was more pronounced in women than
in men [25]. It is also important to consider whether
MSG-induced increases in blood pressure account for
the increased incidence of headaches observed in the
present as well as previous studies [13,14]. Although
earlier work suggested that elevated blood pressure
causes headaches [26-28], more recent work does not
support a strong association. For example, in a large
population of Icelandic men and women, it was found
that elevated systolic blood pressure was inversely corre-
lated with migraine headache in both men and women
[29]. There is also no difference in mean or systolic
blood pressure in women with chronic daily headache
and women without this condition [30]. These findings
suggest that mechanisms other than hypertension may
explain MSG-induced headaches.
Glutamate has also been shown to dilate intracranial
and extracranial blood vessels through a peripheral
NMDA receptor mechanism that involves the release of
nitric oxide [31-33]. Many therapeutically employed
vasodilators appear to cause headaches as one of their
side effects [34]. For example, infusion of nitroglycerin
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to dilation of extracerebral arteries [35,36]. In a recent
study in migraine headache patients, infusion of calci-
tonin gene related peptide (CGRP), a potent neuropep-
tide vasodilator and migraine headache inducer, was
shown to induce vasodilation of arteries only on the side
of the migraine headache pain [37]. On the other hand,
vasodilation itself is not able to induce pain that occurs
only when periovascular nerve endings are sensitized.
This shows that a neural factor, i. e. sensitization, seems
to be related to chronic MSG administration [38]. We
speculate that it could be vasodilation of extracranial
blood vessels through peripheral NMDA receptor activa-
tion that mediates MSG headaches [39].
Baseline salivary concentrations of glutamate did not
increase over the 5 days of MSG intake, however, post
MSG glutamate concentrations increased over the 5 day
period. Glutamate has an apparent half-life of about
30 min, which suggests that it would be completely
cleared from the blood within 4 hrs of ingestion of MSG
[14]. Previously, it was reported that a single oral dose of
150 mg/kg MSG resulted in peak blood glutamate con-
centrations of a little over 400 μM, which occurred 30-
45 min after ingestion [14]. This suggests that salivary
glutamate concentrations are about 25-50% of blood
concentrations. It has been suggested that as much as
40% of a 150 mg/kg oral dose of MSG is removed by
and stored in skeletal muscle [14,40]. Increased peak
levels in the saliva over the 5 days could reflect satur-
ation of storage sites in the skeletal muscle. Animal re-
search suggests that after systemic administration of
MSG (50 mg/kg i.v.) there is a rapid rise in glutamate
concentration in the masseter muscle that is associated
with significant mechanical sensitization of muscle noci-
ceptors [15]. It is likely that oral MSG consumption
increases glutamate concentration in the masseter muscle
of human subjects and that this underlies the mechanical
sensitization of the masseter muscle seen in the present
study.
Although the MSG was dissolved in sugar free lemon
soda, which we have previously found masks the taste of
MSG [13], the vast majority of subjects correctly identi-
fied the substance administered to them when asked at
the end of each 5 days session. Considering the signifi-
cant increase in adverse effects, which occurred during
MSG ingestion, this result is understandable. Neverthe-
less, it does mean that we cannot consider this study
truly blind, and this lack of subject blinding might have
influenced findings that relied on psychophysical assess-
ments, such as PPT and PPTol, and reporting of side
effects. However, it should be noted that even though
PPT and PPTol were assessed in two jaw closing mus-
cles, significant differences were only found for the mas-
seter muscle. This suggests that even if subjects thoughtthey knew what they were receiving their responses were
not reflective of any systematic bias. Also, the adminis-
tration of placebo can induce adverse effects such as
headache, which complicates clarification of adverse
reactions induced by MSG [41]. Though adverse effects
of headache in the placebo week also could be observed
in the result of the present study, it was seen to a signifi-
cantly lesser extent than in the MSG week. This may
imply that an accumulation of MSG by oral administra-
tion could be a factor best avoided by TMD and head-
ache patients. Mechanical sensitization of masseter
muscles is one of the typical symptoms of TMD and
there is a well-known overlap between painful TMD and
headache [42].Conclusion
In conclusion, the present study suggests that individuals
who consume elevated amounts of MSG in their diet are
more likely to suffer from headaches and have masseter
muscle sensitivity, two symptoms associated with myo-
fascial TMD. Although far from definitive, the present
findings may indicate that there is a link between diet
and susceptibility to the development of chronic orofa-
cial pain conditions that include TMD and headache. If
future studies can confirm a link, dietary modification
could become an important part of treatment aimed at
ameliorating symptoms associated with these chronic
craniofacial pain conditions.
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